SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 218 filers reported holding SAGE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $309,708 | -52.5% | 15,049 | +8.4% | 0.04% | -49.4% |
| Q2 2023 | $652,622 | +17.3% | 13,880 | +4.7% | 0.08% | +11.3% |
| Q1 2023 | $556,320 | +126.2% | 13,258 | +105.6% | 0.07% | +121.9% |
| Q4 2022 | $245,952 | +12.3% | 6,449 | +15.1% | 0.03% | +3.2% |
| Q3 2022 | $219,000 | +3.8% | 5,601 | -14.3% | 0.03% | +10.7% |
| Q2 2022 | $211,000 | -76.8% | 6,533 | -76.2% | 0.03% | -73.3% |
| Q1 2022 | $908,000 | +261.8% | 27,424 | +365.4% | 0.10% | +262.1% |
| Q4 2021 | $251,000 | +10.1% | 5,893 | +14.5% | 0.03% | 0.0% |
| Q3 2021 | $228,000 | -0.4% | 5,148 | +27.9% | 0.03% | -3.3% |
| Q2 2021 | $229,000 | -79.1% | 4,026 | -72.6% | 0.03% | -82.1% |
| Q1 2021 | $1,098,000 | +425.4% | 14,669 | +506.7% | 0.17% | +265.2% |
| Q4 2020 | $209,000 | +260.3% | 2,418 | +588.9% | 0.05% | -6.1% |
| Q4 2017 | $58,000 | – | 351 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,966,688 | $120,204,000 | 10.81% |
| Integral Health Asset Management, LLC | 230,000 | $14,058,000 | 4.30% |
| Asymmetry Capital Management, L.P. | 102,462 | $6,262,000 | 4.02% |
| ACUTA CAPITAL PARTNERS, LLC | 225,000 | $13,752,000 | 3.74% |
| DAFNA Capital Management LLC | 158,306 | $9,676,000 | 3.14% |
| Bain Capital Life Sciences Investors, LLC | 499,100 | $30,505,000 | 2.84% |
| Boxer Capital, LLC | 1,094,000 | $66,865,000 | 2.31% |
| Palo Alto Investors LP | 590,200 | $36,073,000 | 1.98% |
| Logos Global Management LP | 250,000 | $15,280,000 | 1.96% |
| Bellevue Group AG | 1,579,504 | $96,539,000 | 1.33% |